The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Redox activation of metal-based prodrugs as a strategy for drug delivery
Open accessAbstract
This review provides an overview of metal-based anticancer drugs and drug candidates. In particular, we focus on metal complexes that can be activated in the reducing environment of cancer cells, thus serving as prodrugs. There are many reports of Pt and Ru complexes as redox-activatable drug candidates, but other d-block elements with variable oxidation states have a similar potential to serve as prodrugs in this manner. In this context are compounds based on Fe, Co, or Cu chemistry, which are also covered. A trend in the field of medicinal inorganic chemistry has been toward molecularly targeted, metal-based drugs obtained by functionalizing complexes with biologically active ligands. Another recent activity is the use of nanomaterials for drug delivery, exploiting passive targeting of tumors with nanosized constructs made from Au, Fe, carbon, or organic polymers. Although complexes of all of the above mentioned metals will be described, this review focuses primarily on Pt compounds, including constructs containing nanomaterials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Taylor-Pashow, K. M. L., Della Rocca, J., Xie, Z., Tran, S., & Lin, W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906198y · Cited by 1,522
New trends for metal complexes with anticancer activity
Bruijnincx, P. C., & Sadler, P. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.11.013 · Cited by 1,306
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Self-citationHartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Glutathione-Mediated Delivery and Release Using Monolayer Protected Nanoparticle Carriers
Hong, R., Han, G., Fernández, J. M., Kim, B.-J., Forbes, N. S., & Rotello, V. M. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056726i · Cited by 817
Cited by
Aggregation-Induced Emission: Together We Shine, United We Soar!
Mei, J., Leung, N. L. C., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00263 · Cited by 8,270
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia
Liu, J.-N., Bu, W., & Shi, J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00525 · Cited by 838
Current advances in lanthanide ion (Ln3+)-based upconversion nanomaterials for drug delivery
Yang, D., Ma, P., Hou, Z., Cheng, Z., Li, C., & Lin, J. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00155a · Cited by 743
Toxicity of Metal Compounds: Knowledge and Myths
Egorova, K. S., & Ananikov, V. P. (2017) · Organometallics · doi:10.1021/acs.organomet.7b00605 · Cited by 703
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Organoiridium Complexes: Anticancer Agents and Catalysts
Liu, Z., & Sadler, P. J. (2014) · Accounts of Chemical Research · doi:10.1021/ar400266c · Cited by 573
Yuan, Y., Kwok, R. T. K., Tang, B. Z., & Liu, B. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411811w · Cited by 474
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Smith, B. R., Eastman, C. M., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501105n · Cited by 372
Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway
Li, S.-R., Bu, L.-L., & Cai, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01014-x · Cited by 352
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Self-citationMin, Y., Li, J., Liu, F., Yeow, E. K. L., & Xing, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308834 · Cited by 309
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Feng, L., Li, C., Liu, L., Wang, Z., Chen, Z., Yu, J., Ji, W., Jiang, G., Zhang, P., Wang, J., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10019 · Cited by 268
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
The Prodrug Platin‐A: Simultaneous Release of Cisplatin and Aspirin
Pathak, R. K., Marrache, S., Choi, J. H., Berding, T. B., & Dhar, S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308899 · Cited by 255
Metadata
- Authors
- Graf, N., & Lippard, S. J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 64
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2095122846
- Cited by
- 523
- References
- 70
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.